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Abstract
Background: An increasing number of countries in sub-Saharan Africa are changing to artemisinins
combination therapy (ACT) as first or second line treatment for malaria. There is an urgent need to assess
the safety of these drugs in pregnant women who may be inadvertently exposed to or actively treated with
ACTs.
Objectives: To examine existing published evidence on the relationship between artemisinin compounds
and adverse pregnancy outcomes and consider the published evidence with regard to the safety of these
compounds when administered during pregnancy.
Methods: Studies on ACT use in pregnancy were identified via searches of MEDLINE, EMBASE, Cochrane
and Current Contents databases. Data on study characteristics, maternal adverse events, pregnancy
outcomes and infant follow up were extracted.
Results: Fourteen relevant studies (nine descriptive/case reports and five controlled trials) were
identified. Numbers of participants in these studies ranged from six to 461. Overall there were reports on
945 women exposed to an artemisinin during pregnancy, 123 in the 1st trimester and 822 in 2nd or 3rd
trimesters. The primary end points for these studies were drug efficacy and parasite clearance. Secondary
endpoints were birth outcomes including low birth weight, pre-term birth, pregnancy loss, congenital
anomalies and developmental milestones. While none of the studies found evidence for an association
between the use of artemisinin compounds and increased risk of adverse pregnancy outcomes, none were
of sufficient size to detect small differences in event rates that could be of public health importance.
Heterogeneity between studies in the artemisinin and comparator drugs used, and in definitions of adverse
pregnancy outcomes, limited any pooled analysis.
Conclusion: The limited data available suggest that artemisinins are effective and unlikely to be cause of
foetal loss or abnormalities, when used in late pregnancy. However, none of these studies had adequate
power to rule out rare serious adverse events, even in 2nd and 3rd trimesters and there is not enough
evidence to effectively assess the risk-benefit profile of artemisinin compounds for pregnant women
particularly for 1st trimester exposure. Methodologically rigorous, larger studies and post-marketing
pharmacovigilance are urgently required.
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Every year over 50 million pregnancies occur in areas
where malaria is endemic, mostly in sub-Saharan Africa.
Malaria can have serious consequences for the mother
and her baby. In regions where malaria transmission is
unstable, pregnant women are at high risk of developing
severe malaria, spontaneous abortion, stillbirth or prema-
ture delivery[1]. In high transmission regions, infected
pregnant women are often asymptomatic but parasitae-
mia can cause maternal anaemia and low birth weight
(LBW), a leading cause of infant morbidity and mortality.
About 8–14% of LBWs and 3–8% of infant mortality in
sub-Saharan Africa are attributable to pregnancy-associ-
ated malaria (PAM)[2].
The WHO recommends a three-pronged approach to con-
trol of malaria during pregnancy which includes effective
case management, intermittent preventive treatment
(IPT) and insecticide-treated nets (ITN). Until recently,
WHO recommendations for case management during any
trimester of pregnancy were chloroquine (CQ), or sul-
phadoxine-pyrimethamine (SP) in CQ-resistant areas
and, alternatively, quinine in areas where neither were
effective. There is limited information on the safety profile
of most antimalarials used for treatment or prevention of
malaria in pregnancy. In a period of increasing parasite
resistance to inexpensive, conventional antimalarials such
as chloroquine, SP and quinine, there is a pressing need to
identify drugs which have the most favourable harm-ben-
efit balance for these vulnerable patients [3,4]. Artemisi-
nins are a potentially valuable alternative as they are
highly effective, act rapidly and are well-tolerated. In addi-
tion, they have the potential to reduce the transmission of
malaria and to slow development of resistance[5]. In
2002, after a detailed review of published and unpub-
lished data, a WHO expert committee concluded that
artemisinins could be used during the second or third tri-
mesters if no suitable alternative was available[6] How-
ever, treatment in the first trimester was not
recommended unless the life of the woman was at risk
because of concerns raised by animal experiments which
suggested that artemisinins might be teratogenic and
cause foetal resorption. Further studies have confirmed
the embryotoxic effects of artemisinin and its derivatives
in animals, including primates, with risk being confined
to a defined period of gestation [7,8]. However it remains
unknown how these findings translate to man. Because of
these safety 'signals' from animal models, there is an
urgent need to establish the safety profile of this class of
drugs in pregnancy. By June 2006, 37 countries in Africa
had adopted ACTs as the first or second line treatment
policy [9] and consequently pregnant women are likely to
be increasingly exposed to ACTs; many women will be
exposed in the first trimester before they are aware of their
pregnancy. This review examines all published and ongo-
ing studies reporting exposure to artemisinins during
pregnancy and discusses their safety during pregnancy.
Methods
Electronic searches were made using MEDLINE/PubMed,
EMBASE (1980 – July 2006) databases and through the
Cochrane Central Register of Controlled Trials (CEN-
TRAL). Reference lists from identified articles and confer-
ence abstracts, including those of the Multilateral
Initiative on Malaria (MIM) conference, 2005, and the
American Society of Tropical Medicine and Hygiene
(ASTMH) annual meeting, 2005, were reviewed. The
National Institute of Health's list of clinical trials was
searched.
Studies on exposure of pregnant women with Plasmodium
falciparum malaria to any artemisinin derivative in, irre-
spective of whether the participants were symptomatic,
have been included in this review. The following data
were extracted from reports: setting, year, study design,
sample size, characteristics of study participants, drug reg-
imen, and outcomes of interest. Outcomes of interests
were: (1) maternal serious adverse events (fatal, life-
threatening or requiring hospitalization); (2) maternal
non-serious adverse events (3) adverse pregnancy out-
comes (miscarriage, stillbirth, preterm delivery, low birth
weight, neonatal death, congenital abnormality, develop-
mental delay).
The internal and external validity of each study was
assessed based on reporting comprehensiveness, the rep-
resentativness of the study population, how bias and con-
founding factors were accounted for, and the power of the
study.
Description of studies
Sixty-nine studies of artemisinin-related drugs were iden-
tified. However, 55 reports were excluded because they
were review papers, animal studies, or because study par-
ticipants were not pregnant women. Among the fourteen
studies that had reported maternal and foetal outcomes of
treatment with an artemisinin derivative in pregnancy,
five were randomized trials (RCT) and nine were descrip-
tive non-randomized studies. Overall these represent
1,121 women who had been exposed to an artemisinin
compound during pregnancy (242 in RCTs and 879 in
observational studies). Taking into account inclusion of
women in more than one of the studies reported from the
Thai-Burmese border, reports were found of 945 pregnan-
cies exposed to an artemisinin compound (123 in the 1st
trimester and 822 in 2nd or 3rd trimesters). The design,
characteristics of the study population, type of interven-
tion and outcomes of each study included in the review
are shown in Table 1.Page 2 of 10
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Five RCTs of artemisinin in pregnant patients have been
reported [10-14]. A randomized trial in Nigeria studied 45
pregnant women treated with artemether alone or in com-
bination with mefloquine, but provided only limited
information regarding the safety of artemether because of
inconsistent infant follow up[14]. In Thailand, an effec-
tiveness and safety trial compared artesunate plus meflo-
quine with quinine in 57 pregnant women. This study
excluded women who had taken antimalarials within the
previous 28 days and those who had over 4% parasitized
red cells. The study population comprised predominantly
milder cases. Specific neurological evaluation of mothers
was performed weekly using established tests and infants
were assessed for physical and neurological development
at 12 or 24 months [10]. Three of the comparative trials
were conducted in antenatal clinics (ANCs) on the Thai
Burmese Border. They compared different drug regimens
Table 1: Description of the studies included in the review on the use of artemisinin in pregnancy.
Study site, year Reference Study Population Antimalarial treatment Primary Outcomes
Randomized trials*
Nigeria, 1994–1997 [14] Pregnant women infected with P. falciparum 
malaria after treatment failure§
1) Artemether IM + mefloquine n = 22
2) Artemether IM n = 23
Artemether overall dosage: 3.2–9.6 mg/kg
Parasitaemia at day 28; AEs
Foetal outcomes; infant neurodevelopment
Thailand, 1995–1998 [10] Pregnant women infected with P. falciparum 
malaria§
1)Quinine n = 29
2)Artesunate+ mefloquine n = 28
Artesunate overall dose: 12 mg/kg
Time to parasite & fever clearance; anaemia; 
AEs; neurological examination
Perinatal assessment; birth outcomes; infant 
physical and neurological assessment
TBB, 1995–1997 [12] Pregnant women with uncomplicated P. 
falciparum malaria
1)Quinine n = 42
2)Artesunate+mefloquine n = 66
Artesunate overall dose: 12 mg/kg
Parasite clearance; anaemia; AEs; 
neurological deficit
Birth outcomes; infant developmental 
milestones
TBB, 1997–2000 [13] Pregnant women with uncomplicated P. 
falciparum malaria
1)Quinine+clindamycin n = 65
2) Artesunate n = 64
Artesunate overall dose: 12 mg/kg
Treatment failure at day 42 or before 
delivery; anaemia; AEs
Birth outcomes; infant developmental 
milestones
TBB, 2001–2003 [11] Pregnant women with uncomplicated P. 
falciparum or mixed malaria
1)Quinine n = 42
2) Artesunate atovaquone-proguanil n = 39
Artesunate overall dose: 12 mg/kg
Fever, parasite clearance; treatment failure 
at day 63; anaemia; AEs
Birth outcomes; infant developmental 
milestones
Case series
China, 1976–1980 [15] Pregnant women infected with P. falciparum 
or P vivax malaria§
Trimesters (n): 3rd (1), 2nd (5)
Artemisinin IM or Artemether
Overall artemisinins dose: 500–900 mg
Therapeutic effects and adverse reactions 
for mother and child
TBB, 1992–1996 [17] Pregnant women with uncomplicated multi-
drug resistant P. falciparum or mixed malarial 
infection
Trimesters (n): 3rd & 2nd (74), 1st (16)
Artesunate alone or with mefloquine; or 
Artemether+mefloquine
Overall artemisinins dose: 12–16 mg/kg
Treatment failure at day 42; anaemia; ADR; 
neurological deficit
Birth outcome; infant neurological 
development
TBB, 1991–1996 [18] Pregnant women with uncomplicated multi-
drug resistant P. falciparum malarial infection 
after treatment failure
Trimesters (n): 3rd & 2nd (74), 1st (16)
Artesunate alone or with mefloquine; or 
Artemether+mefloquine
Overall artemisinins dose: 12–16 mg/kg
Treatment failure at day 42; anaemia; ADR; 
neurological deficit
Birth outcome; infant neurological 
development
TBB, 1992–2000 [16] Pregnant women with uncomplicated multi-
drug resistant P. falciparum or mixed malarial 
infection
Trimesters (n): 3rd (211), 2nd (201), 1st (42)
Artesunate alone or with mefloquine; 
clindamycin atovaquone-proguanil;or 
coartemether, artemether IM
Overall artemisinins dose: 12–16 mg/kg
Treatment failure at day 42; anaemia; ADR; 
neurological deficit
Birth outcome; infant developmental 
milestones
TBB 1999–2001 [19] Pregnant women with multi-drug resistant P. 
falciparum or mixed malarial infection
Trimesters (n): 3rd & 2nd (24), 1st (3)
Artesunate+atovaquone-proguanil
Artesunate overall dose: 12–14 mg/kg
Treatment failure at day 42; parasite 
clearance; AEs
Birth outcomes
TBB 2000–2001 [20] Pharmacokinetic study: pregnant women 
with multi-drug resistant P. falciparum or 
mixed malarial infection
Trimesters (n): 3rd (13) & 2nd (11)
Artesunate+atovaquone-proguanil
Artesunate overall dose: 12 mg/kg
Pharmacokinetic parameters; AEs (including 
ECG); parasite clearance
Birth outcomes
Gambia, 1999 [41] Pregnant women participating in mass 
prevention campaign
Trimesters (n): 1st (77)
Artesunate + SP
Artesunate overall dose: 200 mg
MDA 1° aim: malaria transmission
Pregnancy outcomes
Sudan, 1997–2001 [22] Pregnant women infected with P. falciparum 
malaria after treatment failure§
Trimesters (n): 3rd (15), 2nd (12), 1st (1)
Artemether IM
Artemether overall dose: 480 mg
Treatment failure at day 28; anaemia; 
neurological deficit
Birth outcomes
Sudan, 2004–2005 [23] Pregnant women infected with 
uncomplicated P. falciparum malaria§
Trimesters (n): 3rd (22), 2nd (10)
Artesunate + SP
Artesunate overall dose: 200 mg
Treatment failure at day 28; anaemia
Birth outcomes
* 2nd and 3rd trimesters only
§100% symptomatic/febrile
Abbreviation: ADR: adverse drug reaction; AE: adverse event; ECG: electrocardiograph; IM: intramuscular injection; NR: not reported; Q: quinine; 
A: artemisinin derivative; A+M: artesunate+mefloquine; TBB: Thai-Burmese borderPage 3 of 10
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third trimester pregnancies. In 2000, a report of 108 preg-
nant women randomized to receive quinine or artesunate
plus mefloquine was published [12]. This was followed in
2001 by a report of a randomized trial of artesunate versus
quinine plus clindamycin in 129 pregnant women [13].
More recently, the results of a trial of 81 pregnant women
randomized to receive quinine or artesunate-atovaquone-
proguanil has been published [11]. Women who pre-
sented with a first malaria episode were recruited exclud-
ing those with complicated or severe malaria. Detailed
information on outcome was available. A high level of
efficacy of the artemisinin derivatives was reported in each
study and the drugs were well tolerated.
Descriptive studies
The first descriptive report of the use of artemisinin deriv-
atives during pregnancy came from China. Wang et al
reported the outcomes of six pregnancies exposed to
either artemisinin or artemether. Children of these
women were examined 5 to 10 years later for congenital
malformation, physical and neurodevelopmental evalua-
tion. No adverse events were reported for the mother or
the infants [15].
McGready et al reported the outcome of case-series preg-
nancies exposed to artemisinins on the Thai-Burmese bor-
der in three succeeding publications [16-18]. The latest
publication of 2001 encompasses all cases seen between
1992–2000 (461 women with 539 artemisinin-based
treatments) including women described in previous pub-
lications [12,13]. Overall, there was 11% loss to follow
up. A subgroup of 44 women was exposed inadvertently
during their first trimester. In addition, two publications
report on the treatment of 27 pregnant patients with
atovaquone-proguanil plus artesunate[19,20]. The second
publication [20], focuses on the pharmacokinetics prop-
erties of the drugs in 24 of these women. This group of
studies provides the largest and most detailed record on
the use of artemisinins in pregnancy.
During a mass drug administration campaign in the Gam-
bia, 287 pregnant women were accidentally exposed to
treatment with artesunate plus SP, including 77 who were
exposed during the first trimester of pregnancy [21]. Both
active and passive surveillance were used to maximize
ascertainment of pregnancy outcomes. Reliable case ascer-
tainment and outcome measurement was available for
births notified within seven days of delivery, as these new-
borns were thoroughly examined by a paediatrician.
In Sudan, Adam et al have reported on two studies
[22,23]. The first consisted of the follow-up of 28 sympto-
matic pregnant women who received intramuscular arte-
mether after previous treatment failure with CQ or
quinine. Women were assessed for neurological defects.
There was one first trimester exposure which resulted in a
normal newborn. The second study described 32 sympto-
matic pregnant women treated with artesunate plus SP. In
both studies, women and their infants were followed up
systematically (at birth and one year of age).
Ashley et al reported accidental exposure to artemisinin
compounds during pregnancy in three clinical trials for
the treatment of uncomplicated P. falciparum malaria
[24]: they documented the inadvertent exposures to dihy-
droartemisinin-piperaquine of one woman at 11 weeks
gestation and another at 18 weeks gestation [25,26]. In
Uganda, four pregnant women were accidentally exposed
in their 1st trimester to artemether-lumefantrine during a
trial [27]. All these women delivered normal babies.
Results
Maternal adverse events and pregnancy outcomes in the
artemisinin group and comparison groups (where appli-
cable) are summarized in Tables 2 and 3 respectively.
Maternal adverse events
Overall, artemisinin derivatives were well tolerated; none
of the studies reported serious adverse event (SAE) attrib-
uted to the use of artemisinin. There were seven maternal
deaths reported in total: three women exposed to an
artemisinin (two on the Thai-Burmese border and one
during the mass drug administration campaign in the
Gambia), three with unknown exposure (two reports
from RCTs on the Thai-Burmese border and one in the
Gambia) and one not exposed from the Gambia study.
Cause of death was known for only five women [severe
malaria and anaemia (1), liver abscess (1), post-partum
haemorrhage (3)]. Other maternal adverse events were
described clearly only in the studies conducted at the
Thai-Burmese border. In these studies, adverse events that
could potentially be associated with the study drug were
defined as the occurrence of symptoms after treatment not
present at baseline and which occurred before a recrudes-
cence of parasitaemia or a second infection. Data from
Thailand and the Thai Burmese border showed that tinni-
tus and dizziness were significantly less common in the
artemisinin treatment group (range 9–64%) compared to
the quinine arm (45–79%). Although nausea and vomit-
ing were also significantly less frequent in the artesunate-
mefloquine treatment arm in the Thailand study, no sig-
nificant difference was reported in the Thai-Burmese bor-
der trials. Other adverse events were reported with a
similar frequency in each treatment group. The most fre-
quent complaints according to these studies were dizzi-
ness (range 42–45% for the artemisinin group versus 49–
87% for the quinine arm); nausea (range 22–57% and 8–
93% respectively); headache (range 21–30% and 30–50%
respectively); anorexia (range 7–33% and 0–47% respec-Page 4 of 10
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27% respectively). All of these symptoms were also
reported on presentation (dizziness 57–61%; headache
72–75%; anorexia 46–62%, nausea 30%–40% and mus-
cle/joint pain 59–68%) and so the apparent adverse
events may have been due to the underlying malarial epi-
sode. Specific neurological evaluation of mothers was per-
formed in four studies[10,12,17,22]. This included
Romberg's test, assessment of heel-toe ataxia, fine finger
dexterity, auditory acuity and an assessment for nystag-
mus. There was no report of a woman with an adverse
neurological event associated with drug administration.
The studies were too heterogeneous in terms of severity of
disease, drug treatment and outcome measurements, and
numbers to few to pool data for a meta-analysis.
Pregnancy outcomes
Ninety-six percent of the 945 women exposed to an
artemisinin in pregnancy were followed up to delivery.
Twenty (2.1%) had miscarriages, 19 (2%) stillbirths and
11 (1.2%) neonatal deaths. Six (0.6%) congenital abnor-
malities were reported (one left aural atresia, one polythe-
lia, one epidermoid cyst and three not described);
whereas the expected rate of birth defects in developing
countries is about 6% [28]. Of the 214 infants examined
up to at least one year of age only one was reported to be
developmentally delayed. The mother of this infant was
treated with artesunate-atovaquone-proguanil and he was
assessed for motor and neuro-developmental milestones
(no details provided).
Table 2: Safety outcomes: maternal adverse events and pregnancy outcomes in women exposed to artemisinin compounds. 
Randomized trials
Study site, year
Ref
Antimalarial treatment N (% follow up) Outcomes of interests
Maternal Safety¥ Pregnancy outcomes
Nigeria, 1994–1997 [14] 1) Artemether IM + mefloquine n = 22
2) Artemether IM n = 23
45 (100%) Minimal, only A+M: abdominal 
discomfort (9%) and dizziness (9%)
Neonatal jaundice (n = 2 A & n = 1 
A+M)
6 (13%) followed up to 1 year
Thailand, 1995–1998 [10] 1) Quinine n = 29
2) Artesunate+ mefloquine n = 28
60 (95%) Neurological exam: all normal.
Nausea (16%), vomiting (12%), vertigo 
(12%), tinnitus (18%), and 
hypoglycaemia (3%) more frequent in 
Q (p < 0.05). Other no difference: 
Palpitation (6%), blurring vision (11%).
Neonatal jaundice (n = 5 Q & n = 1 
A+M)
46 (81%) followed up to 1 year
TBB, 1995–1997 [12] 1) Quinine n = 42
2) Artesunate+ mefloquine n = 66
108 (85%) Neurological exam
1 maternal death*
Tinnitus (15%) and dizziness (42%) 
more frequent in Q (p < 0.05).
Headache (21%), nausea (45%), 
abdominal pain (28%), vertigo (12%), 
muscle/joint pain (32%), and anorexia 
(35%) no difference with Q (p > 0.05).
Abortions (n = 2 A+M)
46 (49%) followed up to 1 year
Neonatal deaths (n = 2 A+M & n = 1 
Q)
TBB, 1997–2000 [13] 1) Quinine)+ clindamycin n = 65
2) Artesunate n = 64
129 (91%) Tinnitus (9%) more frequent in Q+C (p 
< 0.05). Headache (30%), dizziness 
(41%) nausea (25%), vomiting (8%), 
abdominal pain (18%), rash (9%), 
contractions (35%), muscle/joint pain 
(12%), and anorexia (42%) no 
difference with Q+C (p > 0.05).
Stillbirths (n = 1 A & n = 1 Q+C)
Congenital abnormality: midline 
epidermoid cyst (n = 1 Q+C)
Neonatal deaths (n = 1 A & n = 2 
Q+C)
72 (62%) followed up to 1 year
TBB, 2001–2003 [11] 1)Quinine n = 42
2) Artesunate atovaquone-proguanil 
(AAP) n = 39
81 (91%) 1 maternal death**
Tinnitus (24%) more frequent in Q (p < 
0.05).
Stillbirth (n = 1 not specified maternal 
death)
Congenital abnormalities: polythelia (n 
= 1 AAP); cleft lip & palate (n = 1 AAP); 
aural atresia (n = 1 Q)
Neonatal deaths (n = 1 A & n = 2 
Q+C)
59 (78%) followed up to 1 year
Developmentally delayed (n = 1 AAP)
TOTAL No 1st trimester, P. falciparum or 
mixed malaria 17% to 100% 
symptomatic 242 artemisinins 
exposures
423 (94%) 2 maternal deaths
Neurological exam in 2 studies
Stillbirths (n = 1 A; n = 1 Q+C & n 
= 1 unknown)
Congenital abnormality: (n = 2 A 
& n = 2 Q)
Neonatal deaths (n = 4 A+M & n = 
5 Q)
229 (59%) infant followed up to 1 
year
¥ Prevalence of possible ADRs are only reported for the artemisinin treatment groups
* cause unrelated to malaria (treatment group NR)
** caused by a ruptured liver abscess (treatment group NR)
Abbreviation: ADR: adverse drug reaction; AE: adverse event; IM: intramuscular injection; NR: not reported; Q: quinine; A: artemisinin derivative; 
A+M: artesunate+mefloquine; TBB: Thai-Burmese borderPage 5 of 10
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None of the studies included in this review revealed an
increased risk of serious maternal adverse effects, adverse
birth outcomes, or neuro-development deficits associated
with the use of an artemisinin drug during pregnancy.
However, these studies were not designed to assess safety
endpoints and, although they were sufficiently powered
to answer the original study objective, the studies were
under-powered to detect rare safety outcomes, or small
differences in adverse event rates, between the compari-
son groups.
The very low prevalence of congenital anomalies reported
can partly be explained by the complex nature of birth
defect ascertainment; ideally a dysmorphologist should
have assessed all newborns for abnormalities that would
not be detected by an untrained physician. It was also not
possible to assess the expected rate of adverse birth out-
comes in any of the study settings due to the lack of back-
ground population data on rates for abortions, stillbirths
and congenital abnormalities. Four studies which looked
for neurological damage following artemisinin exposure
revealed no indication of neurotoxicity. However, in the
light of recent debates about the potential ototoxicity of
the artemisinins, further studies conducting thorough
auditory evaluation before and after treatment may be
needed [29-31].
The studies reviewed were highly heterogeneous in terms
of treatment used, outcomes assessment, population and
follow up rate. Different artemisinin drug regimens were
used with varying control treatments as a comparator and
six studies did not have a control group but compared the
rates of adverse birth outcome to community rates derived
from separate studies. Most of the studies used an artem-
isinin derivative combined with another drug, which adds
to the difficulty of teasing out individual drug effects and
restricts comparison between studies. Four studies used
artesunate in combination with mefloquine; use of the
latter in pregnancy has caused concern because of an
Table 3: Safety outcomes: maternal adverse events and pregnancy outcomes in women exposed to artemisinin compounds: 
Descriptive studies.
Study site, year Ref Antimalarial treatment N (% Follow-up) Outcomes of interests
Maternal Safety Pregnancy outcomes
Overall 1st trimester expo-
sures
China, 1976–1980 [15] Artemisinin IM or Artemether 6 (100%) No adverse effect 6 (100%) followed up at 5–9 
year
None
TBB, 1992–2000 [16] Artesunate alone or with 
mefloquine; clindamycin 
atovaquone-proguanil; 
coartemether, artemether IM
461 (89%) No ADRs (pruritus)
Maternal deaths (n = 2)*
Abortions 4.8% (n = 20)
Stillbirth 1.8% (n = 7)
Congenital abnormalities 
0.8%: anencephaly (n = 1); 
midline epidermoid cyst (n = 
1)
Abortions 23% (n = 10)
TBB 1999–2001 [19] Artesunate+atovaquone-
proguanil
27 (100%) Symptoms possible ADRs: 
Headache (42%); muscle/joint 
pain (30%); abdominal pain 
(42%); anorexia (40%); nausea 
(25%); vomiting (10%); rash 
(15%); dizziness (70%), 
tinnitus (24%); contraction 
(15%) and sleep disturbance 
(8%)
Neonatal deaths (n = 1) Normal deliveries and 
healthy newborns
Gambia, 1999 [41] Artesunate + SP 325 (88%) Maternal deaths (n = 1)** Stillbirth (n = 11)
Congenital abnormalities: 
umbilical hernia (n = 1); 
undescended testis; (n = 1) 
Neonatal deaths (n = 8)
Not reported
Sudan, 1997–2001 [22] Artemether IM 28 (100%) NR Neonatal deaths (n = 1) Normal delivery and 
healthy newborn
Sudan, 2004–2005 [23] Artesunate + SP 32 (100%) Giddiness and nausea (13%)
Neurological exam.
Neonatal deaths (n = 1) None
TOTAL 123 1st trimester, P. 
falciparum or mixed malaria 
7% to 100% symptomatic 
945 artemisinin exposures
879 (90%) 3 maternal deaths
Neurological exam in 2 
studies
Abortions n = 20
Stillbirths (n = 18)
Congenital abnormality: 
(n = 4) Neonatal deaths (n 
= 11)
65 (15%) infant followed 
up to 1 year
Abortions n = 10
* One maternal death was due to severe malaria and anaemia, the other died of causes unrelated to malaria.
** For 1 maternal death the exposure status could not be confirmed; verbal autopsies indicate that the deaths were due to postpartum 
haemorrhage.
Abbreviation: ADR: adverse drug reaction; AE: adverse event; IM: intramuscular injection; NR: not reported; Q: quinine; A: artemisinin derivative; 
A+M: artesunate+mefloquine; TBB: Thai-Burmese borderPage 6 of 10
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drug during pregnancy in one study [32] although this
was not found in others. [33-36]. The methods used to
monitor adverse event and birth outcomes also differed
widely between the studies. Under-estimates of adverse
outcomes cannot be ruled out, particularly for early preg-
nancy loss in the mass drug administration campaign in
the Gambia. There are no statistics on expected rate of
early pregnancy loss, and determining the prevalence of
spontaneous abortion is difficult. In western countries,
miscarriages occur in 10 to15% of pregnancies, mostly
during the first few weeks. The prevalence of miscarriages
is likely to be even higher in resource poor setting. When
assessing maternal AEs, there is the methodological chal-
lenge of differentiating between the effect of malaria and
its treatment which is difficult to do. Furthermore, the
severity of malaria episode varied between the different
study populations since three included women who had
already experienced a treatment failure whilst nine others
included some asymptomatic women. Furthermore, the
study in the Gambia was preventive; as the majority of the
participants in this study are unlikely to have had malaria,
lower rates of adverse birth outcomes would be expected
compared to those of studies of malaria case manage-
ment. The allocation of interventions could have been
influenced by many factors particularly for the non-rand-
omized studies, such as prognostic factors (severity or
malaria attack rates, parasite resistance, mother's age, gra-
vidity, other drugs etc.), which could themselves influence
birth outcome and treatment response. There is, therefore,
a potential for selection and detection bias. Maternal
malaria has been associated with stillbirth, abortion and
LBW and these adverse end-points are also considered as
possible indicators of an adverse event related to drug
administration[1]. Furthermore, none of these studies
controlled for other drug use, which could potentially
influence pregnancy outcomes.
Most of the information on artemisinin exposure during
pregnancy comes from studies conducted in Southeast
Asia, at the antenatal clinics of the Shoklo Malaria
Research Unit among women of the Karen ethnic minor-
ity. The RCTs had robust design and randomly allocated
treatment groups, although the investigators were not
blinded to the treatment group. Follow up of infants var-
ied between these three studies (49 to 80%) and only 46
infants were followed up to one year of age and examined
for developmental abnormalities in the non-comparative
studies. The women enrolled in these studies are likely to
be representative of this population group (Karen ethnic
minority) as over 90% of the women in the studied Thai-
Burmese border region attend ANCs. These findings can-
not be extrapolated directly to sub-Saharan Africa consid-
ering geographic differences in parasite species, resistance
pattern, transmission intensity and host immunity.
A number of studies of artemisinin treatment in preg-
nancy are in progress (Table 4), which will contribute fur-
ther to knowledge on the safety of these drugs. However,
except for the phase IV study being conducted by the Cen-
tres for Disease Control in Tanzania, these studies focus
on 2nd and 3rd trimester pregnancies. The results of animal
studies suggest that if there is a safety issue related to the
administration of artemisinins in pregnancy this is likely
to occur very early in pregnancy. Only 123 documented
first trimester exposures have been reported and this does
not provide enough evidence to determine safety. Moreo-
ver, an "all or nothing rule" seems to apply for exposure
during the first weeks of pregnancy. Animal experiments
suggest that congenital abnormalities occur only after
exposure over a narrow dose range and over a limited
period of time and that exposure usually lead to a normal
pregnancy outcome or death of the foetus. Developmen-
tal toxicity studies in the monkey confirmed findings from
rodent studies; with embryo death induced at therapeutic
dose ranges [37]. The teratogenic effect is thought to
involve red blood cells production, erythropoiesis, which
implies the human sensitive period would be within the
first trimester of pregnancy [38]. An effect of ACTs on early
pregnancy loss will be difficult to detect, especially in
communities where artemisinins are likely to be used
most frequently. More extensive studies are needed that
will be able to detect rarer outcomes and any congenital
abnormalities that might result from exposure in the first
trimester of pregnancy. Ethical constraints will prohibit
randomized trials of artemisinins in the first trimester of
pregnancy in most communities where alternatives exist
until more information on safety has been obtained.
Thus, data will largely have to come from observational
studies.
Unfortunately, most countries in sub-Saharan Africa do
not have the infrastructure and resources for routine phar-
macovigilance and very few have a formal system for rou-
tine collection of data on possible drug related adverse
effects [39]. In industrialized countries, a variety of post-
marketing surveillance techniques is used. Case reports
and case series are the first source of information to detect
adverse events in pregnancy. Although these are useful in
the generation of hypotheses of a possible safety signal,
specific pharmaco-epidemiological studies using a cohort
or case-control approach are required to evaluate tera-
togenic risk. The main factors impeding the implementa-
tion of pharmacovigilance in poor countries include
limited access to healthcare facilities, availability of most
prescription drugs from the informal market, poor label-
ling of medicines, counterfeit and sub-standard pharma-
ceutical products, a high level of illiteracy, poor record
keeping and a shortage of qualified healthcare profession-
als. Special pharmaco-epidemiological studies will be
needed to assess the safety profile of a product's use out-Page 7 of 10
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Table 4: Ongoing Studies (Information extracted from Malaria in Pregnancy (MiP)* Database [42] on 05/02/2007).
Study Setting Design & Drug Regimen Outcome Status
(start date-completion date)
Safety/Efficacy prevention trial in pregnancy
Ifakara, Tanzania CDC/IHRDC-IMPACT Randomised open label, n = 1200 (400 
per arm)
IPTp
Control: SP 2 doses
Intervention:
1. SP monthly
2. SP+artesunate monthly
1°: Placental parasitaemia and AEs
2°: Maternal illness and parasitaemia at 
delivery, birth outcome (BW, 
Gestational age, foetal and infant health), 
childhood developmental milestones
Recruitment concluded; ongoing follow 
up (01/03-ongoing)
Safety/Efficacy Treatment trial in Pregnancy
ANC at Muheza Hospital, Tanzania GMP Randomised open label, target (Phase III)
n = 350 2nd or 3rd trimesters
Control: SP
Intervention: SP+amodiaquine, 
Amodiaquine+artesunate, 
Chloroporguanil-dapsone
1°: Treatment failure at day 28; 
Treatment outcome (parasite/fever 
clearance, parasite recrudescence)
2°: Foetal viability and birth outcomes 
(preterm delivery, foetal death, perinatal/
neonatal mortality, neonatal 
abnormality); maternal AE 
(hypoglycaemia)
Recruitment completed (01/04–07/06)
Shoklo Malaria Research Unit (SMRU) 
ANC, Thailand UNICEF-UNDP-World 
Bank-WHO-TDR
Randomized intervention trial
n = 250 2nd or 3rd trimesters Group 1: 
Artesunate
Group 2: Co-artemether (artemether/
lumefantrine)
1°: Treatment outcome at day 42 or at 
delivery (parasite/fever clearance, 
parasite recrudescence)
2°:Gametocyte carriage; 
pharmacokinetic parameters; histo-
pathology examination of the placenta
Currently recruiting (06/02/2004–31/12/
2008)
Bangladesh
WHO
Randomised controlled trial
n = 684
Control: placebo rectal capsule
Intervention: Artesunate rectal capsule
Pregnancy outcomes Currently recruiting (10/11/2003-
ongoing)
Malawi; Prof Meshnick, UNC Randomised open label, n = 141 2nd or 
3rd trimesters Control: SP
Intervention: SP+artesunate or 
SP+azithromycin
1°: Parasitological failure rates; parasite 
clearance time; fever clearance times and 
incidence rate of adverse events
2°: Prevalence rate of abortions; still 
births; peripheral parasitaemia at 
delivery; placental malaria and of 
maternal anaemia
Recruitment completed (09/2003–10/
2005)
Efficacy/Pharmacokinetic trial in Pregnancy
Mozambique
UCT, South Africa
Non-Randomized openLabel, target n = 
30 2nd or 3rd trimester pregnant
HistoricalControl
Intervention: SP+artesunate
1°: Pharmacokinetic parameters
2°: gametocyte carriage, maternal AE & 
birth outcomes
Currently recruiting (03/2006–09/2008)
Kinshasa, DRC, NIH-NICHD Dose-equivalence trial: part of 
investigational new drug application
n = 60 2nd or 3rd trimester
Control: SP
Intervention: Artesunate-mefloquine 
combinations
Pharmacokinetic parameters Recruitment completed (07/2005–12/
2005)
Pharmacovigilance: Post-marketing surveillance
Tanzania, CDC Pharmacovigilance surveillance system: 
part of a large ongoing study to look at 
district wide use of ACTs 1st trimester
Control: SP
Intervention: SP+Artesunate
Pregnancy outcome and status of child Ongoing (2005–2007)
A partnership between Novartis WHO-
TDR and the Government of Zambia. 
[43]
Pregnancy Registry
Prospective active surveillance cohort.
Expected n = 1600
Control: SP
Intervention: artemether-lumefantrine
Maternal and neonatal outcomes 
examined
Ongoing (2005)
* MiP is a consortium of experts in the field of malaria funded by the Bill and Melinda Gates Foundation to review current research and develop 
future research strategy for malaria in pregnancy. One of the key objectives of MiP is to create a database containing all published and unpublished 
research and a trial registry on malaria in pregnancy.
Abbreviations: ACT: artemisinin combination therapy; AE: adverse events; ANC: antenatal care; BW: birthweight; CDC: Centers for Disease 
Control & Prevention; GMP: Gates Malaria Partenership; DRC: Democratic Republic of the Congo; IHRDC: Ifakara Health Research and 
Development Centre; IPTp: intermittent presumptive treatment for pregnancy; NIH-NICHD: National Institutes of Health-The National Institute 
of Child Health and Human Development; RCT: randomized controlled trials; SP: sulphadoxine-pyrmethamine; TBB: Thai-Burmese Border; UNC: 
University of North Carolina; UCT: University of Cape Town; WHO-TDR: World Health Organization – The Special Programme for Research and 
Training in Tropical Diseases
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surveillance systems could use the existing sentinel demo-
graphic surveillance sites (DSS), which already undertake
regular household visits to obtain more information on
drug usage and adverse effects during pregnancy. How-
ever, these studies are expensive and not sustainable in the
long term and should be restricted to newer products or
following identification of new safety concerns for an
older drug. Antenatal clinics (ANC) could make a useful
platform for routine surveillance, as a high proportion of
pregnant women attend an ANC at least once during preg-
nancy in sub-Saharan Africa [40]. It is necessary to
develop a more pragmatic pharmacovigilance system that
can be linked to a routine health information system and
ideally a mix of different approaches should be used to
assess the safety profile of individual drugs for pregnant
patients.
Conclusion
Malaria in pregnancy is a major public health issue and
infected pregnant women need prompt treatment with
effective drugs. Although artemisinin derivatives and
combinations have an excellent efficacy profile, there is
very limited data on the safety of artemisinin use during
pregnancy particularly in sub-Saharan Africa. Although a
few studies of the safety and efficacy of artemisinins dur-
ing pregnancy are currently underway, these will not pro-
duce data on the safety of artemisinins during the first
trimester of pregnancy. Post-marketing pharmacovigi-
lance of artemisinin use during pregnancy is needed
urgently as ACT is implemented in almost all countries in
Africa. Innovative pharmacovigilance tools, methods and
systems are needed to monitor the safety of artemisinins
and other antimalarials.
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